Cellectis (NASDAQ:CLLS) Share Price Passes Below 50 Day Moving Average - What's Next?

Key Points

• Cellectis shares have dropped below their fifty day moving average of $2.82, trading as low as $2.48, signaling potential concerns among investors.
• The company received a recent upgrade to a "hold" rating from Wall Street Zen, while the consensus rating remains a "Buy" with a price target of $4.00.
• Despite a significant revenue increase in its last earnings report, Cellectis reported a loss of ($0.24) EPS, missing the consensus estimate, which further adds to the challenges the company faces.

Cellectis S.A. (NASDAQ:CLLS - Get Free Report)'s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.82 and traded as low as $2.48. Cellectis shares last traded at $2.84, with a volume of 410,737 shares traded.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Cellectis to a "hold" rating in a research report on Saturday, September 20th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $4.00.

Cellectis Stock Down 15.5%

The firm's 50 day moving average is $2.82 and its two-hundred day moving average is $1.94. The firm has a market cap of $157.85 million, a P/E ratio of -3.46 and a beta of 3.03. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.58.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The company had revenue of $18.19 million for the quarter, compared to analyst estimates of $10.07 million. Cellectis had a negative return on equity of 68.05% and a negative net margin of 100.69%. As a group, research analysts anticipate that Cellectis S.A. will post -0.46 EPS for the current fiscal year.

Institutional Trading of Cellectis

Hedge funds have recently bought and sold shares of the stock. OLD Mission Capital LLC acquired a new stake in Cellectis during the 1st quarter worth approximately $31,000. Acadian Asset Management LLC grew its stake in shares of Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 26,461 shares in the last quarter. Millennium Management LLC bought a new position in shares of Cellectis during the 4th quarter worth approximately $962,000. Long Focus Capital Management LLC grew its stake in shares of Cellectis by 2.2% during the 1st quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock worth $5,849,000 after acquiring an additional 100,000 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Cellectis by 228.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company's stock worth $5,856,000 after acquiring an additional 3,284,409 shares in the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.